Intestinal Research最新文献

{"title":"Transabdominal intestinal ultrasound parameters as intermediate treatment targets in a treat-to-target strategy for moderate-to-severe ulcerative colitis.","authors":"Longxi Yun, Zhaojue Wang, Qingli Zhu, Yalong Zhu, Hui Xu, Bei Tan, Wenbo Li, Yue Li","doi":"10.5217/ir.2025.00286","DOIUrl":"https://doi.org/10.5217/ir.2025.00286","url":null,"abstract":"<p><strong>Background/aims: </strong>This study aimed to investigate the prognostic value of early post-induction intestinal ultrasound (IUS) findings in predicting long-term clinical outcomes among patients with moderate-to-severe ulcerative colitis (UC).</p><p><strong>Methods: </strong>This retrospective, single-center study consecutively enrolled patients with moderate-to-severe, left-sided or extensive UC. Clinical endpoints were assessed at the end of follow-up or 1 year after induction therapy (for patients with at least 1 year of follow-up) and categorized as clinical remission (Short Clinical Colitis Activity Index [SCCAI] ≤ 2) or non-remission (SCCAI > 2). Patients who experienced a negative disease course before the evaluation point were classified as clinical non-remission.</p><p><strong>Results: </strong>A total of 56 patients were included. The bowel wall thickness (BWT; 5.1 ± 1.7 mm vs. 6.0 ±1.4 mm; P= 0.032) and Milan ultrasound criteria (MUC; 8.3 ± 3.2 vs. 9.9 ± 2.2; P= 0.029) evaluated at early follow-up IUS were lower for patients reaching longterm clinical remission. Patients with BWT < 5 mm on early follow-up IUS (83% vs. 45%; P= 0.006) or MUC < 6.2 (100% vs. 45%; P< 0.001) had a significantly higher rate of long-term clinical remission. Kaplan-Meier analysis revealed a lower cumulative probability of a negative disease course in patients with BWT < 5 mm (P= 0.025) or MUC < 6.2 (P= 0.025). Cox regression analysis identified BWT ≥ 5 mm as an independent predictor of a negative disease course.</p><p><strong>Conclusions: </strong>BWT <5 mm and MUC < 6.2 may serve as intermediate targets for IUS-guided \"treat-to-target\" strategy, offering a practical approach to improve longterm clinical remission in patients with moderate-to-severe UC.</p>","PeriodicalId":14481,"journal":{"name":"Intestinal Research","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2026-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147972558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Appropriate J-pouch volume associated with improved clinical outcomes and long-term quality of life in patients with ulcerative colitis after ileal pouch-anal anastomosis: results from China UC Pouch Center Union.","authors":"Weimin Xu, Zhujiang Dai, Wenjun Ding, Long Cui, Xiaojian Wu, Wei Zhou, Zhao Ding, Peng Du","doi":"10.5217/ir.2026.00003","DOIUrl":"https://doi.org/10.5217/ir.2026.00003","url":null,"abstract":"<p><strong>Background/aims: </strong>A well-functioning and well-constructed pouch is crucial for the long-term quality of life (QOL) in ulcerative colitis (UC) patients after ileal pouch-anal anastomosis (IPAA). What pouch volume is appropriate to construct to maintain satisfactory pouch function for better long-term prognosis remains unknown.</p><p><strong>Methods: </strong>UC patients who underwent IPAA from January 2008 to January 2024 in our pouch surgery centers affiliated with the China UC Pouch Center Union were enrolled. The primary outcomes were the occurrence of postoperative complications and impaired long-term QOL.</p><p><strong>Results: </strong>A total of 222 eligible UC patients with a median follow-up time of 8.0 years (interquartile range, 4.0-10.3 years) were enrolled. Among the patients, 117 (52.7%) had a pouch with volume <120 mL, whereas 105 (47.3%) had a pouch volume ≥120 mL. We found that patients with pouch volume ≥ 120 mL were more likely to achieve significantly improved long-term QOL (P= 0.013), better bowel function (P= 0.030) as well as have decreased risk of late postoperative complications (P= 0.005), mainly presented as pouchitis (P= 0.039). Furthermore, we demonstrated that a small pouch with volume < 120 mL is an independent risk factor for the development of late postoperative complications (odds ratio, 2.157; P= 0.013) and impaired long-term QOL (odds ratio, 2.049; P= 0.018).</p><p><strong>Conclusions: </strong>A J-pouch volume ≥ 120 mL could be a considerable option for colorectal surgeons in pouch configurations to achieve better long-term prognosis.</p>","PeriodicalId":14481,"journal":{"name":"Intestinal Research","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147837767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety of Janus kinase inhibitors compared to biologic therapy in patients with inflammatory bowel disease.","authors":"Gursimran S Kochhar, Himsikhar Khataniar, Parambir S Dulai, Aakash Desai","doi":"10.5217/ir.2025.00232","DOIUrl":"https://doi.org/10.5217/ir.2025.00232","url":null,"abstract":"<p><strong>Background/aims: </strong>There is a paucity of data regarding the comparative safety of Janus kinase inhibitors (JAKi) compared to biologic therapy in inflammatory bowel disease (IBD).</p><p><strong>Methods: </strong>A retrospective cohort study was conducted using the U.S. Collaborative Network to assess the risk of adverse events in patients with IBD on JAKi compared to biologic therapies (tumor necrosis factor inhibitor, ustekinumab or vedolizumab). Outcomes assessed included infections, major adverse cardiovascular events (MACE), malignancy, venous thromboembolism (VTE), gastrointestinal perforations and laboratory abnormalities within 2 years. 1:1 propensity score matching (PSM) was performed.</p><p><strong>Results: </strong>There were 3,186 patients in the JAKi cohort (mean age 44.3 ± 17.1, 46.5% male sex, 85.7% ulcerative colitis, 72% tofacitinib) and 60,462 patients in the biologic cohort. After PSM, there was no difference in the risk of bacterial (adjusted odds ratio [aOR], 1.08; 95% confidence interval [CI], 0.82-1.43), viral (aOR, 1.06; 95% CI, 0.84-1.32), or fungal infections (aOR, 1.10; 95% CI, 0.84-1.44), MACE (aOR, 0.72; 95% CI, 0.47-1.10), malignancy (aOR, 0.98; 95% CI, 0.71-1.35), and VTE (aOR, 0.95; 95% CI, 0.67-1.34). This was consistent in subgroup analyses based on IBD type, JAKi type and age group. There was a higher risk of low-density lipoprotein ≥ 190 mg/dL (aOR, 1.78; 95% CI, 1.03-3.05) and grade 3 or higher lymphopenia (aOR, 2.28; 95% CI, 1.60-3.26) in the JAKi cohort. There was no difference in the 4-year risk of MACE or malignancy in the tofacitinib cohort compared with the biologic cohort.</p><p><strong>Conclusions: </strong>Our real-world study did not show an increased risk of adverse events except severely elevated LDL and lymphopenia in patients on JAKi compared to biologic therapy.</p>","PeriodicalId":14481,"journal":{"name":"Intestinal Research","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147837787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dyslipidemia and hyperglycemia synergistically increase the risk of intestinal barrier dysfunction: evidence from a case-control study in China.","authors":"Chao Zhang, Dandan Lin, He Yu, Ying Yang, Zongtao Chen","doi":"10.5217/ir.2025.00163","DOIUrl":"https://doi.org/10.5217/ir.2025.00163","url":null,"abstract":"<p><strong>Background/aims: </strong>Previous evidence regarding the combined effects of metabolic disorders on intestinal barrier function (IBF) remains limited. We hypothesized that metabolic disorders interact to increase the risk of intestinal barrier dysfunction.</p><p><strong>Methods: </strong>This retrospective case-control study included 4,289 individuals who underwent IBF assessment. Controls with normal biomarker levels were propensity score-matched to cases with abnormal D-lactic acid, diamine oxidase (DAO), or endotoxin. Logistic regression and interaction models were applied to assess associations between metabolic indicators and intestinal barrier dysfunction.</p><p><strong>Results: </strong>Hypertension (odds ratio [OR], 1.36; 95% confidence interval [CI], 1.20-1.55; P< 0.001), dyslipidemia (OR, 1.70; 95% CI, 1.49-1.96; P< 0.001), and hyperglycemia (OR, 1.80; 95% CI, 1.57-2.08; P< 0.001) were significantly associated with intestinal barrier dysfunction. Subgroup analyses confirmed that dyslipidemia and hyperglycemia were independently associated with elevated DAO, D-lactic acid, and endotoxin levels. Both multiplicative and additive interactions were observed between key metabolic factors. Particularly, dyslipidemia and hyperglycemia showed significant additive interactions (relative excess risk due to interaction, 0.79 [95% CI, 0.19-1.35, P= 0.008]; attributable proportion due to interaction, 0.29 [95% CI, 0.06-0.46, P= 0.008]; synergy index, 1.82 [95% CI, 1.13-3.41, P= 0.008]). When stratified by age and sex, broadly similar trends were observed in participants aged ≥ 50 years and in males.</p><p><strong>Conclusions: </strong>Dyslipidemia and hyperglycemia are associated with intestinal barrier dysfunction and show a synergistic combined effect. Individuals with both should receive prioritized IBF monitoring and early metabolic intervention to protect barrier integrity.</p>","PeriodicalId":14481,"journal":{"name":"Intestinal Research","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147837800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"One-year effectiveness and safety of ustekinumab treatment in patients with ulcerative colitis: an Asan-Crohn's and Colitis Association in Daegu-Gyeongbuk (CCAiD) multicenter real-world cohort study.","authors":"Ji Eun Baek, Min Kyu Kim, Eun Soo Kim, Kyeong Ok Kim, Hyeong Ho Jo, Sung Wook Hwang, Sang Hyoung Park, Byung Ik Jang, Eun Young Kim, Sung Kook Kim, Suk-Kyun Yang, Byong Duk Ye","doi":"10.5217/ir.2025.00258","DOIUrl":"https://doi.org/10.5217/ir.2025.00258","url":null,"abstract":"<p><strong>Background/aims: </strong>This study aimed to evaluate the 1-year effectiveness and safety of ustekinumab (UST) in Korean patients with ulcerative colitis (UC).</p><p><strong>Methods: </strong>We conducted a multicenter retrospective study of UC patients who received UST between January 2021 and October 2023. The primary endpoint was clinical remission at week (W) 8. Secondary endpoints included clinical remission at W16-20 and W52-56; corticosteroid-free clinical remission at W8, W16-20, and W52-56; clinical response at the same time points; endoscopic remission at W16-20 and W52-56; UST interval shortening and persistence through W52-56; and adverse events (AEs).</p><p><strong>Results: </strong>Sixty patients were included. After excluding one patient in clinical remission at baseline, 49.2% (29/59) achieved clinical remission at W8. Clinical remission rates were 59.3% (35/59) at W16-20 and 55.9% (33/59) at W52-56. Endoscopic remission was achieved in 15.3% (9/59) at W16-20 and 11.9% (7/59) at W52-56. The 12-month UST persistence rate was 84.9%. Multivariable analysis identified factors associated with clinical remission at W52-56: higher body mass index at baseline (adjusted odds ratio [aOR], 1.26; 95% confidence interval [CI], 1.00-1.57; P< 0.05), concomitant immunomodulator use (aOR, 4.69; 95% CI, 1.04-21.06; P= 0.04), and endoscopic improvement at W16-20 (aOR, 13.47; 95% CI, 2.87-63.30; P< 0.01), while prior exposure to advanced therapies was associated with lower remission (aOR, 0.20; 95% CI, 0.04-0.98; P< 0.05). AEs occurred in 24 patients (40.0%), with 1 serious AE (1.7%).</p><p><strong>Conclusions: </strong>UST showed favorable 1-year effectiveness and an acceptable safety profile in Korean patients with UC.</p>","PeriodicalId":14481,"journal":{"name":"Intestinal Research","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2026-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147722679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrated endoscopic and medical approaches for Crohn's disease-associated strictures.","authors":"Rintaro Moroi, Yoichi Kakuta, Atsushi Masamune","doi":"10.5217/ir.2025.00317","DOIUrl":"https://doi.org/10.5217/ir.2025.00317","url":null,"abstract":"<p><p>Crohn's disease (CD) frequently results in fibrostenotic or anastomotic intestinal strictures, a major cause of morbidity despite advances in medical therapy. Endoscopic management is a central component of stricture treatment, providing organ-preserving alternatives to surgery. This review summarizes the current evidence for 3 principal endoscopic modalities: endoscopic balloon dilation (EBD), endoscopic stricturotomy (ES), and stent-based interventions. EBD, the most widely used technique, is recommended as the first-line therapy for short, non-angulated strictures, with consistently high technical and clinical success; however, repeat dilations are required during long-term follow-up. ES using an electrosurgical knife offers a targeted solution for fibrotic or EBD-refractory strictures, achieving high technical success, even in anatomically complex lesions, although delayed bleeding may occur. Stent-based interventions, including self-expandable metallic stents and biodegradable stents, have recently re-emerged as an option for intermediate-length or difficult strictures, including those beyond the typical length limit for EBD or ES; short-term, removable, anti-migration stents show a more favorable safety profile. These 3 modalities provide complementary strengths, and treatment selection should be individualized based on stricture length, morphology, location, associated inflammation, prior surgery, and endoscopist expertise. An integrated approach that optimizes endoscopic and medical therapies is essential for improving long-term outcomes and minimizing the need for repeated surgery in patients with CD.</p>","PeriodicalId":14481,"journal":{"name":"Intestinal Research","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2026-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147722709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Portulaca oleracea L. extract in patients with irritable bowel syndrome.","authors":"Kwangwoo Nam, Jung Ho Choi, Yong Sung Kim, Seong Lee, Jee Hun Park, Hyeongjoo Kim, Sangyun Lee, Yerin Lee, Doohyuck Lee, Sunghyeok Ryou, Jeong Eun Shin","doi":"10.5217/ir.2025.00200","DOIUrl":"https://doi.org/10.5217/ir.2025.00200","url":null,"abstract":"<p><strong>Background/aims: </strong>Portulaca oleracea is known to have anti-inflammatory and immunoregulatory effects, and also showed positive effect on complete spontaneous bowel movement and bowel symptoms in patients with chronic constipation in a previous study. Thus, we aimed to investigate the impact of P. oleracea in patients with irritable bowel syndrome (IBS).</p><p><strong>Methods: </strong>Patients with IBS defined by ROME IV criteria were enrolled between July 2022 and April 2023. Patients were randomly assigned to P. oleracea or placebo group and took drugs for 8 weeks. Clinical data including gastrointestinal and IBS symptoms, laboratory tests including inflammatory and immunologic laboratory markers, and stool tests including fecal calprotectin and stool microbial analysis were evaluated at the baseline, week 4, and week 8.</p><p><strong>Results: </strong>A total of 108 patients were initially enrolled and 101 patients were finally included in the analysis. There was significant improvement during 8 weeks in P. oleracea group compared to placebo group in the aspect of gastrointestinal and IBS-related bowel symptoms (Gastrointestinal Symptom Rating Scale total score: from 44.1 to 31.7 vs. from 41.4 to 39.9; IBS-Symptom Severity Score total score: from 232.0 to 120.6 vs. from 202.7 to 178.2), especially in the aspect of abdominal pain. Interleukin-6 (IL-6) was significantly decreased during 8 weeks in P. oleracea group, although there was no significant difference between 2 groups. In addition, increase in IL-6 during study period was significantly associated with dysbiosis in stool microbial analysis. There was no significant adverse event.</p><p><strong>Conclusions: </strong>P. oleracea has positive impact in patients with IBS showing improvement of immunologic cytokine and stool microbiome.</p>","PeriodicalId":14481,"journal":{"name":"Intestinal Research","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2026-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147722715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The duration of prior anti-tumor necrosis factor agents is associated with the effectiveness of vedolizumab in patients with ulcerative colitis: a real-world multicenter retrospective study.","authors":"Taku Kobayashi, Tadakazu Hisamatsu, Satoshi Motoya, Minoru Matsuura, Toshimitsu Fujii, Reiko Kunisaki, Tomoyoshi Shibuya, Ken Takeuchi, Sakiko Hiraoka, Hiroshi Yasuda, Kaoru Yokoyama, Noritaka Takatsu, Atsuo Maemoto, Toshiyuki Tahara, Keiichi Tominaga, Masaaki Shimada, Nobuaki Kuno, Mary Cavaliere, Kaori Ishiguro, Jovelle L Fernandez, Toshifumi Hibi","doi":"10.5217/ir.2024.00126","DOIUrl":"10.5217/ir.2024.00126","url":null,"abstract":"<p><strong>Background/aims: </strong>Previous literature suggests that the response of patients with ulcerative colitis to vedolizumab may be affected by previous biologic therapy exposure. This real-world study evaluated vedolizumab treatment effectiveness in biologicnon-naïve patients.</p><p><strong>Methods: </strong>This was a multicenter, retrospective, observational chart review of records from 16 hospitals in Japan (December 1, 2018, to February 29, 2020). Included patients who had ulcerative colitis, were aged ≥ 20 years, and received at least 1 dose of vedolizumab. Outcomes included clinical remission rates from weeks 2 to 54 according to prior biologic exposure status and factors associated with clinical remission up to week 54.</p><p><strong>Results: </strong>A total of 370 eligible patients were included. Clinical remission rates were significantly higher in biologic-naïve (n=197) than in biologic-non-naïve (n=173) patients for weeks 2 to 54 of vedolizumab treatment. Higher clinical remission rates up to week 54 were significantly associated with lower disease severity (partial Mayo score ≤ 4, P= 0.001; albumin ≥ 3.0, P= 0.019) and the duration of prior anti-tumor necrosis factor α (anti-TNFα) therapy (P= 0.026). Patients with anti-TNFα therapy durations of < 3 months, 3 to < 12 months, and ≥ 12 months had clinical remission rates of 28.1%, 32.7%, and 60.0%, respectively (P= 0.001 across groups).</p><p><strong>Conclusions: </strong>The effectiveness of vedolizumab in biologic-non-naïve patients was significantly influenced by duration of prior anti-TNFα therapy. (Japanese Registry of Clinical Trials: jRCT-1080225363).</p>","PeriodicalId":14481,"journal":{"name":"Intestinal Research","volume":" ","pages":"281-292"},"PeriodicalIF":4.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13153848/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144215807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can lifestyle restrictions prevent relapse in ulcerative colitis? A focus on quality of life.","authors":"Jihye Park","doi":"10.5217/ir.2026.00027","DOIUrl":"10.5217/ir.2026.00027","url":null,"abstract":"","PeriodicalId":14481,"journal":{"name":"Intestinal Research","volume":"24 2","pages":"195-196"},"PeriodicalIF":4.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13153846/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147837838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world effectiveness and safety of carotegrast methyl in patients with ulcerative colitis: a multicenter retrospective cohort study.","authors":"Ryoji Koshiba, Kazuki Kakimoto, Takuya Inoue, Makoto Sanomura, Mitsuyuki Murano, Hiroaki Ito, Yoshihiko Nakanishi, Ken Kawakami, Noboru Mizuta, Keijiro Numa, Naohiko Kinoshita, Kei Nakazawa, Azusa Hara, Yuki Hirata, Naokuni Sakiyama, Shoko Arimitsu, Takako Miyazaki, Shiro Nakamura, Hiroki Nishikawa","doi":"10.5217/ir.2025.00066","DOIUrl":"10.5217/ir.2025.00066","url":null,"abstract":"<p><strong>Background/aims: </strong>Carotegrast methyl is a novel small-molecule drug that inhibits α4 integrin. It is prescribed for up to 6 months in patients with moderate ulcerative colitis who have demonstrated an inadequate response to or intolerance of 5-aminosalicylic acid. However, only a few clinical trials have been conducted to assess its effectiveness. This study aimed to evaluate the efficacy and safety of carotegrast methyl in patients with ulcerative colitis.</p><p><strong>Methods: </strong>This multicenter retrospective study included patients with active ulcerative colitis treated with carotegrast methyl between March 2022 and October 2024. The primary outcome was the clinical remission rate following treatment with carotegrast methyl. Secondary outcomes included the clinical response rate, predictors of clinical remission, ulcerative colitis relapse rate after discontinuing carotegrast methyl, and incidence of adverse events.</p><p><strong>Results: </strong>This study included 62 patients who received carotegrast methyl treatment. The median duration of administration was 84 days, with 48.4% of patients achieving clinical remission at the time of carotegrast methyl discontinuation. In 42 patients with corticosteroid/advanced therapies-naive disease, the clinical remission rate was 54.8%. Multivariate analysis identified the baseline partial Mayo score as an independent predictor of clinical remission. Among those who achieved clinical remission, 34.8% experienced a relapse with a median time to relapse of 152 days. Adverse events occurred in 8 patients, but none were serious.</p><p><strong>Conclusions: </strong>Carotegrast methyl demonstrated good efficacy and safety, potentially benefiting patients with low baseline disease activity. This drug may be a useful treatment option to consider before systemic corticosteroid therapy for ulcerative colitis.</p>","PeriodicalId":14481,"journal":{"name":"Intestinal Research","volume":" ","pages":"316-328"},"PeriodicalIF":4.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13153854/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144821410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}